Rigel Pharmaceuticals, Incorporated

Bristol-myers Squibb Compnay

Nuvation Bio Inc.

Other

Eli Lilly and Company

Bristol Meyers Squibb Company

Rigl Pharmaceutical, Inc.

Ihab S Darwish

Jiaxin Yu

Rajinder Paul Singh

Hui Hong

Somasekhar Bhamidipati

Xiang Xu

Vanessa Taylor

Sambaiah Thota

Rao Kolluri

Esteban Masuda

Simon Shaw

Zhushou Luo

Yan Chen

Pingyu Ding

Todd M Kinsella

Marina Gelman

Sacha Holland

Matthew Duncton

Ankush Argade

Jeffrey Clough

Robert Michael Borzilleri

Upender Velaparthi

Jayakumar Sankara Warrier

Peiying Liu

Andy Atuegbu

Hasibur Rahaman

Matt Duan

Lu Chou

Dazhong Fan

Gary Park

Dane A Goff

Son Minh Pham

Jeremy D Pettigrew

Jayakanth Kankanala

Chetan Padmakar Darne

Henry Lu

David Hung

Mark Irving

Christopher Paul Miller

Vadim Markovtosov

Beth Fernandez

Vadim Markovtsov

Emily Stauffer

Chetan Padmakar Dame

Sambiah Thota

Eileen Goldstein

Rao S S Kolluri

Chrystelle Lamagna

Disclosed embodiments concern compounds according to Formula I In some embodiments, the compounds are useful as kinase inhibitors, such as interleukin receptor associated kinases (IRAK) inhibitors. Also disclosed are compositions comprising such inhibitors, and methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent a kinase-associated disease or condition, particularly an IRAK-associated disease or condition.

Tricyclic IRAK inhibitors

Disclosed herein are embodiments of a pyrazole compound according to formula I. Compositions comprising the compound, and a method for making the composition also are disclosed. The composition may comprise a carrier, such as a polymer and/or the composition may be a spray-dried formulation. Also disclosed is a method for using the compound and/or composition. The compound and/or composition may be useful to inhibit an IRAK protein and/or to ameliorate, treat and/or prevent an IRAK-associated disease or condition in a subject.

Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations

Disclosed herein are embodiments of a method for treating a disease or condition in a subject, comprising administering to the subject, a pyrazole compound according to formula I. The compound may be administered as a composition, such as a spray-dried formulation. The disease or condition may be hidradenitis suppurativa, or a lymphoid neoplasm, and may be chronic myeloid leukemia or chronic myelomonocytic leukemia.

Method for treating a disease or condition using a pyrazole compound or formulation thereof

Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

RIP1K inhibitors

Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, X, Z, m, p, and Rare as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or more members of the TGF-β superfamily, and can be used to treat disease by blocking such activity.

TGF-β inhibitors

The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, such as a compound of Formula I: or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, to products containing the same, as well as to methods of their use and preparation.

Anti-cancer nuclear hormone receptor-targeting compounds

Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to inhibit a RIP1 kinase in vivo or ex vivo, and also may treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

RIP1 inhibitory compounds and methods for making and using the same

The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.

Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.

Tyrosine kinase inhibitors

Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The compounds may have a structure according to Formula I  The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

Heterocyclic RIP1 inhibitory compounds

Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, X, Z, m, p, and Rare as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or more members of the TGF-&#x3b2; superfamily, and can be used to treat disease by blocking such activity.

TGF-&#x3b2; inhibitors

Growing community of inventors

San Carlos, CA, United States of America

Ihab S Darwish